Entering text into the input field will update the search result below

Flex Pharma's (FLKS) CEO Bill McVicar on Q4 2017 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Start Time: 09:00 January 1, 0000 9:34 AM ET

Flex Pharma, Inc. (FLKS)

Q4 2017 Earnings Conference Call

March 07, 2018, 09:00 AM ET


Bill McVicar - CEO

Tom Wessel - CMO

John McCabe - CFO

Elizabeth Woo - SVP, IR and Corporate Communications


Jotin Marango - ROTH Capital

Mara Goldstein - Cantor Fitzgerald

Michael Higgins - Ladenburg

Roger Tung - Jefferies


Good day, ladies and gentlemen, and welcome to the Q4 2017 Flex Pharma, Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions]. As a reminder, this conference is being recorded.

I would like to introduce your host for today's conference, Ms. Elizabeth Woo, Senior Vice President of Investor Relations and Corporate Communications. Ma’am, you may begin.

Elizabeth Woo

Thank you, Bruce. Good morning and thank you for joining us to discuss Flex Pharma’s fourth quarter and full year 2017 financial results as well as our recent progress and outlook.

Earlier today, we issued a press release announcing recent business highlights and detailing our fourth quarter and full year 2017 results. You can find these documents on our Web site at flexpharma.com.

Today, we will be making certain forward-looking statements about future expectations, plans, events and circumstances, including statements about our strategy, future operations and the development of our consumer and drug product candidates, plans for future potential product candidates and studies and our expectations regarding our capital allocation and cash resources. These statements are based on our current expectations, and you should not place undue reliance on these statements.

Actual results may differ materially due to our risks and uncertainties, including those detailed in the risk factors section of our 10-K filed with the SEC

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.